Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9368)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 21, 2021 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol 2021; 27(19): 2312-2324 [PMID: 34040324 DOI: 10.3748/wjg.v27.i19.2312] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i19/2312.htm |
| Number | Citing Articles |
| 1 |
Sarosh Ahmed Khan, Rida Zahid, Muhammad Amir. Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant. ACG Case Reports Journal 2024; 11(4): e01327 doi: 10.14309/crj.0000000000001327
|
| 2 |
Jingjing Wang, Xiaozhen Geng, Xin Zhang, Yanfeng Xiao, Wenjun Wang. Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.921084
|
| 3 |
Nicholas Strat, Lauren Sattele, Dirk Elston. A retrospective cohort review of infectious disease findings in patients screened before immunosuppressant therapy. Journal of the American Academy of Dermatology 2023; 89(6): 1282 doi: 10.1016/j.jaad.2023.07.1033
|
| 4 |
Meng‐Hsuan Kuo, Chih‐Wei Tseng, Shih‐Chieh Shao. Letter: Incidence of hepatitis B virus reactivation in patients with psoriasis treated with cytokine inhibitors. Alimentary Pharmacology & Therapeutics 2023; 58(8): 850 doi: 10.1111/apt.17682
|
| 5 |
Galina I. Gridneva, Boris S. Belov, Evgeniia S. Aronova. Chronic hepatitis B in rheumatic diseases: issues of screening and reactivation of infection: A review. Terapevticheskii arkhiv 2024; 96(5): 523 doi: 10.26442/00403660.2024.05.202707
|
| 6 |
Sama Anvari, Keith Tsoi. Hepatitis B Virus Reactivation with Immunosuppression: A Hidden Threat?. Journal of Clinical Medicine 2024; 13(2): 393 doi: 10.3390/jcm13020393
|
| 7 |
Hyeokjun Yun, Jae-Sik Jeon, Jae Kyung Kim. Analysis of Inflammatory and Thyroid Hormone Levels Based on Hepatitis A and B Virus Immunity Status: Age and Sex Stratification. Viruses 2024; 16(8): 1329 doi: 10.3390/v16081329
|
| 8 |
Qing Ma, Wenjun Li, Wenying Wu, Mei Sun. Exploring the active ingredients and mechanisms of Liujunzi decoction in treating hepatitis B: a study based on network pharmacology, molecular docking, and molecular dynamics simulations. Computer Methods in Biomechanics and Biomedical Engineering 2024; : 1 doi: 10.1080/10255842.2024.2427117
|
| 9 |
Sneha Patel, Anand Kumthekar. Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice. Rheumatology and Therapy 2022; 9(1): 49 doi: 10.1007/s40744-021-00397-7
|
| 10 |
Ricardo Romiti, André Luís da Silva Hirayama, Adriana Maria Porro, Heitor de Sá Gonçalves, Luciane Donida Bartoli Miot, Sandra Maria Barbosa Durães, Silvio Alencar Marques. Infections in the era of immunobiologicals. Anais Brasileiros de Dermatologia 2024; 99(2): 167 doi: 10.1016/j.abd.2023.08.004
|
| 11 |
G. I. Gridneva, B. S. Belov, E. S. Aronova. Chronic viral hepatitis B and rheumatic diseases: Modern view on problem. Medical alphabet 2022; (29): 20 doi: 10.33667/2078-5631-2022-29-20-28
|
| 12 |
Laura Mateu-Arrom, Lluis Puig. Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities. Expert Review of Clinical Pharmacology 2024; 17(4): 363 doi: 10.1080/17512433.2024.2340552
|
| 13 |
Ibrahim Abdulrazag Al-Homood, Nayef Al Ghanim, Mohammad Ibrahim Ahmad Fatani, Albader Hamza Hussein, Abdulaziz Mohammed Alolaiwi, Abdullah Abualiat, Eman Alqurtas, Bedor Abdullah Abdulrahman Alomari, Amr Mohammad Khardaly, Khalidah Ahmed Owdetallah Alenzi, Rayan G. Albarakati, Hajer Yousef Almudaiheem, Ahmed Al-Jedai, Maysa Tariq Yousef Eshmawi. The Saudi consensus recommendations for the management of psoriatic arthritis (2023). Clinical Rheumatology 2024; 43(3): 879 doi: 10.1007/s10067-024-06867-x
|
| 14 |
G. I. Gridneva, E. S. Aronova, B. S. Belov. Chronic hepatitis B in hospitalized rheumatologic patients: problems of screening and reactivation of infection. Modern Rheumatology Journal 2023; 17(5): 67 doi: 10.14412/1996-7012-2023-5-67-72
|
| 15 |
J.M. Carrascosa, L. Puig, I.B. Romero, L. Salgado-Boquete, E. del Alcázar, J.J.A. Lencina, D. Moreno, P. de la Cueva. Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo». Actas Dermo-Sifiliográficas 2022; 113(6): 583 doi: 10.1016/j.ad.2022.01.024
|
| 16 |
J.M. Carrascosa, L. Puig, I.B. Romero, L. Salgado-Boquete, E. del Alcázar, J.J.A. Lencina, D. Moreno, P. de la Cueva. [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2—Management of Special Populations, Patients With Comorbid Conditions, and Risk. Actas Dermo-Sifiliográficas 2022; 113(6): T583 doi: 10.1016/j.ad.2022.01.040
|